Ronald Levy, MD
Palo Alto, CA
Board of Trustees of the Leland Stanford Junior University
Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and director of the Lymphoma Program at Stanford University School of Medicine. He is also the associate director of translational science for the Stanford Cancer Institute. For more than 25 years his research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab (Rituxan®) for the treatment of patients diagnosed with lymphomas. He is using lymphocyte receptors as targets for new therapies for lymphoma, and he is currently conducting clinical trials of in situ therapeutic vaccination. Dr. Levy is a member of the National Academy of Medicine.